Companies: 10,795·Total market cap: $144.5T
Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCENASDAQHealthcare● Active
$2.37
+$0.07(+2.83%)
Market Cap$36596010
P/E Ratio
52W High$5.18
52W Low$1.79
SEC Filings

Grace Therapeutics, Inc. (GRCE) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001444192 · GRCE · NASDAQ · as of Jun 9, 2026

Filing snapshot

558
Total Filings
8-K
Latest Form
2026-06-05
Most Recent
2012
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001444192 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-06-23
Fiscal Year End
Jun 23, 2025
Accession No.
0001140361-25-023259
Primary Document
ef20047573_10k.htm
Source: data.sec.gov · CIK 0001444192 · Accession 0001140361-25-023259

Latest Key Filings

10-QQuarterly Report
10-Q
2026-02-12
8-KCurrent Report
8-K
2026-06-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-27
View
8-KCurrent Report
8-K
2026-04-27
View
8-KCurrent Report
8-K
2026-04-23
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
8-KCurrent Report
8-K
2026-02-12
View
10-QQuarterly Report
10-Q
2026-02-12
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-28
View
8-KCurrent Report
8-K
2026-01-12
View
10-Q/AQuarterly Report (Amended)
10Q/A
2025-11-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
8-KCurrent Report
8-K
2025-11-13
View
10-QQuarterly Report
10-Q
2025-11-13
View
Showing 1–15 of 508 filingsForm 4 / 144 hidden· 558 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001444192  |  Exchange: NASDAQ · Healthcare

Grace Therapeutics, Inc. (NASDAQ: GRCE) has submitted 558 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2012. As a Healthcare sector company with CIK 0001444192, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Grace Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Grace Therapeutics, Inc. 10-K was filed on 2025-06-23 for fiscal year ending 2025. Historical GRCE 10-K annual reports are available from 2008 through 2025.

Investors researching Grace Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

GRCE SEC Filings · 8 questions

Grace Therapeutics, Inc. (GRCE) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 558 filings and access original documents at no cost. Grace Therapeutics, Inc.'s CIK is 0001444192.

GRCE SEC filingsGrace Therapeutics, Inc. SEC documentsfind GRCE 10-K